Stockscreener 앱 받기
1.12
1.32%
-0.02
전일 마감가:
$1.14
열려 있는:
$1.15
하루 거래량:
144.06K
Relative Volume:
0.65
시가총액:
$89.22M
수익:
-
순이익/손실:
$-21.65M
주가수익비율:
-3.3725
EPS:
-0.3321
순현금흐름:
$-15.84M
1주 성능:
+4.17%
1개월 성능:
+38.89%
6개월 성능:
-42.60%
1년 성능:
-43.47%
1일 변동 폭
$1.10
$1.1696
1주일 범위
$1.06
$1.18
52주 변동 폭
$0.7709
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
명칭
Cardiol Therapeutics Inc
전화
-
주소
-
CRDL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.125 | 89.22M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
157.49 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.34 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.61 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.41 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
295.83 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-26 | 개시 | ROTH MKM | Buy |
| 2024-04-22 | 개시 | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
(CRDL) Trading Performance and Risk Management (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Daily Stock Insights (CRDL:CA) - news.stocktradersdaily.com
March Quarterly Activities Report - Investing News Network
March Quarterly Appendix 4C - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Trading Up 6.7% – What’s Next? - Defense World
Profound Medical Corp. - Baystreet.ca
Cardiol Therapeutics Inc. - Baystreet.ca
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors | CRDL Stock News - GuruFocus
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board Amid Phase III Trial Progress - TipRanks
Cardiol Therapeutics Taps 30-Year Pharma Veteran and Ex-Eli Lilly CMO to Strengthen Clinical Strategy - Stock Titan
Cardiol Therapeutics announces annual shareholder meeting By Investing.com - Investing.com India
Cardiol Therapeutics announces annual shareholder meeting - Investing.com
Cardiol Therapeutics Schedules Virtual Annual General Meeting for May 2025 - TipRanks
First patient dosed in Phase IIb imaging for Brain Mets - Investing News Network
(CRDL) Strategic Market Analysis (CRDL:CA) - news.stocktradersdaily.com
A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David ElsleyCardiol Therapeutics - thedeepdive.ca
Long Term Trading Analysis for (CRDL) (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Newsfile
(CRDL) Risk-Controlled Trading Report (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? - Nasdaq
Iridium (IRDM) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Genocea Biosciences (NASDAQ:GNCA) versus Cardiol Therapeutics (NASDAQ:CRDL) Head-To-Head Review - Defense World
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Roth Capital Has Bearish Forecast for CRDL Q1 Earnings - Defense World
Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday - Defense World
Cardiol Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Earns “Buy” Rating from HC Wainwright - Defense World
Northwestern University enrols first subject in trial of drug for pericarditis - Yahoo
(CRDL) Pivots Trading Plans and Risk Controls (CRDL:CA) - news.stocktradersdaily.com
ardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics Commences Phase III Trial for CardiolRx™ in Recurrent Pericarditis - TipRanks
Cardiol Therapeutics starts phase III trial for heart drug - Investing.com Australia
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile
3 Reasons to Sell CSV and 1 Stock to Buy Instead - The Globe and Mail
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics Reports Increased Losses Amid Rising Expenses - TipRanks
HC Wainwright Has Negative Outlook for CRDL FY2025 Earnings - Defense World
H.C. Wainwright maintains $9 target on Cardiol Therapeutics stock By Investing.com - Investing.com UK
Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year Low – Should You Sell? - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Receives “Buy” Rating from HC Wainwright - Defense World
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate - Yahoo Finance
Cardiol Therapeutics advances heart disease treatments By Investing.com - Investing.com South Africa
Stocks In Play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics Advances Heart Disease Treatments with Promising Clinical Results - TipRanks
Cardiol Therapeutics advances heart disease treatments - Investing.com
Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile
Virtu Financial LLC Invests $61,000 in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 5% – Time to Sell? - Defense World
Cardiol Therapeutics Inc (CRDL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.87%
자본화:
|
볼륨(24시간):